Moderna lays out plan for mRNA-1273 vaccine

By The Science Advisory Board staff writers

May 19, 2020 -- Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Based on the results, the company plans to begin a phase III study in July.

In the phase I study, patients were dosed at 25 µg or 100 µg; all participants seroconverted by day 15 after a single dose. Researchers found that mRNA-1273 vaccination-neutralizing antibody titers in eight patients exceeded those seen in convalescent sera. Moreover, the vaccine was generally safe and well-tolerated by participants.

In the phase II study, the company will amend the dose levels, at 50 µg and 100 µg, with the goal of selecting a pivotal dose. The NIAID-led phase I study is also amending doses to include a 50 µg dose level cohort across three age groups.

Phase II and III studies of mRNA-1273 are supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA). They are also supporting the scale-up of mRNA-1273 manufacturing at two Moderna facilities as well as at Lonza facilities, a strategic partner of the company.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here